Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
NEW YORK — A decision in the $100 million creative review for Novartis’ Zelnorm is expected within two weeks, as the review is down to two contenders, Interpublic Group’s Deutsch and Omnicom’s Cline, Davis & Mann, sources said.
Novartis has dropped WPP’s Ogilvy & Mather and Interpublic’s McCann-Erickson from review for its forthcoming remedy for irritable bowel syndrome, according to several sources.
The shops are all based in New York and the review covers only the U.S.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in